The physical parameters and molecular events associated with radiation-induced lung toxicity

Seminars in Radiation Oncology

Volumn 10, Issue 4, 2000, Pages 296-307

  Vujaskovic, Zeljko ^a   Marks, Lawrence B ^a   Anscher, Mitchell S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; LUNG CANCER; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG VOLUME; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW;

EID: 0033784887     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2000.9424     Document Type: Article

References (118)

1. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications
2. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy
3. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
4. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease
5. The role of radiotherapy in the management of malignant thymoma
6. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors
7. Radiation pneumonitis in patients treated for breast cancer
8. Observations on the predictive value of perfusion lung scans on post-irradiation pulmonary function among 210 patients with bronchogenic carcinoma
9. Is radiation treatment volume a predictor for acute or late effect on pulmonary function? A prospective study of patients treated with breast-conserving surgery and postoperative irradiation
10. Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing
11. Prospective study of long-term pulmonary manifestations of mantle irradiation
12. Results of a prospective study evaluating the effects of mantle irradiation on pulmonary function
13. Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease
14. Cancer statistics, 1998
15. Cancer statistics, 1994
16. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung
17. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer: A Hoosier Oncology Group protocol
18. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III NSCLC
19. Radical radiotherapy and chemotherapy in localized inoperable non-small cell lung cancer: A randomized trial
20. Significant effect of adjuvant chemotherapy on survival and locally advanced non-small cell lung cancer
21. Inoperable non-small cell lung cancer: Radiation with or without chemotherapy
22. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial
23. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer
24. Effective chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients
25. Impact of tumor control on survival in carcinoma of the lung treated with irradiation
26. The relationship between tumor response and survival following radiotherapy for carcinoma of the bronchus
27. Local control in medically inoperable lung cancer: An analysis of its importance in outcome and factors determining the probability of tumor eradication
28. Tolerance of normal tissue to therapeutic irradiation
29. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method
30. Optimization of radiation therapy III. A method of assessing complication probabilities from dose-volume histograms
31. The pulmonary effects of thoracic irradiation
32. The role of three dimensional functional lung imaging in radiation treatment planning: The functional dose-volume histogram
33. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung
34. Physical and biological predictors of changes in whole-lung function following thoracic irradiation
35. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis
36. Optimization of 3D radiation therapy with both physical and biological end points and constraints
37. Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation
38. Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation
39. A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data
40. Dose-effect relations for local functional and structural changes of the lung after irradiation for malignant lymphoma
41. Estimation of overall pulmonary function after irradiation using dose-effect relations for local functional injury
42. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation
43. Quantifying local lung perfusion and ventilation using correlated SPECT and CT data
44. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
45. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients
46. The effects of radiation therapy on pulmonary function in carcinoma of the lung
47. Physiologic changes in pulmonary function after radiotherapy for patients with lung cancer and role of regional pulmonary function studies in predicting post-radiotherapy pulmonary function before radiotherapy
48. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study
49. Induction of acute phase gene expression by brain irradiation
50. Induction of c-fos and junB mRNA following in vivo brain irradiation
51. A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis
52. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: Interrelationship between the alveolar macrophage and the septal fibroblast
53. Early alteration in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis
54. Cellular basis of radiation-induced fibrosis
55. Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2
56. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
57. Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2
58. The stress response to ionizing radiation involves c-Abl-dependent phosphorylation of SHPTPl
59. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells
60. Mechanisms of x-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines
61. Ketoconazole attenuates radiation-induction of tumor necrosis factor
62. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B
63. Differences in correlation of mRNA gene expression in mice sensitive and resistant to radiation-induced pulmonary fibrosis
64. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation
65. Intercellular adhesion molecule 1 knockout abrogates radiation induced pulmonary inflammation
66. Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung
67. Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: Comparison between a fibrosis-prone and fibrosis-resistant mouse strain
68. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and 'non-fibrosing' mice during the latent period and early phase after irradiation
69. Magnesium superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: Modulation of irradiation-induced mRNA for IL-1, TNF-a, and TGF-β correlates with delay of organizing alveolitis/fibrosis
70. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation
71. Modulation of gene expression in Syrian hamster embryo cells following ionizing radiation
72. Induction of interleukin 6 by ionizing radiation in a human epithelial cell line: Control by corticosteroids
73. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation
74. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation
75. Modification of tumor microenvironment by cytokine gene transfer
76. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
77. Changes in plasma TGF-β levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis
78. Plasma transforming growth factor β1 as a predictor of radiation pneumonitis
79. Transforming growth factors beta-1 and alpha in chronic liver disease - Effects of interferon alpha therapy
80. Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis
81. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta
82. Transforming growth factor beta levels in rat wound chambers
83. Accelerated healing of incisional wounds in rats induced by transforming growth factor beta
84. Transforming growth factor type-beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
85. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo
86. TGFβ is a strong and fast-acting positive regulator of the level of type 1 plasminogen activator inhibitor mRNA in WI-38 lung fibroblast
87. The reversal of adriamycin-induced healing impairment with chemo attractants and growth factors
88. Reversal of adriamycin impaired would healing by transforming growth factor beta
89. Alterations in pulmonary mRNA encoding procollagens, fibronectin, and transforming growth factor beta precede bleomycin-induced pulmonary fibrosis
90. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis
91. Elevated plasma TGFβ1 levels in breast cancer patients decrease following removal of the tumor
92. Expression of c-erbB2, TGFβ-1 and pS2 genes in primary human breast cancers
93. Elevated plasma levels of TGFβ1 in patients with invasive prostate cancer
94. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases
95. Transforming growth factor β and the cell surface in tumor progression
96. Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy
97. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis
98. Growth factor balance in tumor progression
99. Transforming growth factor beta receptors and mannose-6-phosphate/insulin-like growth factor II receptor expression in human hepatocellular carcinomas
100. Absence of TGFβ receptors and growth inhibitory responses in retinoblastoma cells
101. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability
102. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor
103. M6P/IGF2r gene is mutated in human hepatocellular carcinomas with LOH
104. Frequent loss of heterozygocity on 6q at the mannose-6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors
105. The bovine mannose 6-phosphate/insulin-like growth factor II receptor: The role of arginine residues in mannose 6-phosphate binding
106. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma
107. Latent transforming growth factor beta in serum: A specific complex with alpha-2 microglobulin
108. Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin
109. Redox mechanisms for activation of latent TGF-β
110. Transforming growth factor-β in disease: The dark side of tissue repair
111. Molecular and cellular basis of radiation fibrosis
112. Plasma TGF-beta level in rats after hemithoracic irradiation
113. Radiological and functional assessment of radiation-induced lung injury in the rat
114. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis
115. Normal tissue injury after cancer therapy is a local manifestation of a systemic condition
116. Elevated circulating transforming growth factor beta1 levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin's disease: A possible tumor marker
117. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer
118. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)